Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06610526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 700 to confirmed 731 · Study sites: 37 to 34v12 Show 2 more changesShow less
    • Enrollment target: estimated 700 to confirmed 731
    • Study sites: 37 to 34
  2. Primary and study completion dates: Apr 27, 2027 to May 31, 2027v11
  3. Site details revised at 2 of 37 sitesv10
  4. Site details revised at 2 of 37 sitesv9
  5. Study sites: 35 to 37v8
Show 6 earlier versionsHide 6 earlier versions
  1. Re-verified, no change to tracked fieldsv7
  2. Site details revised at 1 of 35 sitesv6
  3. Site details revised at 1 of 35 sitesv5
  4. Study sites: 33 to 35 Primary and study completion dates: Jun 21, 2027 to Apr 27, 2027 · Start date: Sep 10, 2024 to Aug 23, 2024v4 Show 2 more changesShow less
    • Primary and study completion dates: Jun 21, 2027 to Apr 27, 2027
    • Start date: Sep 10, 2024 to Aug 23, 2024
  5. Study sites: 34 to 33 Start date: Aug 23, 2024 to Sep 10, 2024v3 Show 1 more changeShow less
    • Start date: Aug 23, 2024 to Sep 10, 2024
  6. Study sites: 33 to 34v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.
Trial Details
NCT Number NCT06610526
Lead Sponsor AstraZeneca
Conditions Chronic Kidney Disease
Enrollment 731 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov